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Abstract 
Background: The aim of this study was to assess the relationship between extracorporeal blood flow (EBF) and left 
ventricular (LV) performance during venoarterial extracorporeal membrane oxygenation (VA ECMO) therapy.
Methods: Five swine (body weight 45 kg) underwent VA ECMO implantation under general anesthesia and artificial 
ventilation. Subsequently, acute cardiogenic shock with signs of tissue hypoxia was induced. Hemodynamic and 
cardiac performance parameters were then measured at different levels of EBF (ranging from 1 to 5 L/min) using arte-
rial and venous catheters, a pulmonary artery catheter and a pressure–volume loop catheter introduced into the left 
ventricle.
Results: Myocardial hypoxia resulted in a decline in mean (±SEM) cardiac output to 2.8 ± 0.3 L/min and systolic 
blood pressure (SBP) to 60 ± 7 mmHg. With an increase in EBF from 1 to 5 L/min, SBP increased to 97 ± 8 mmHg 
(P < 0.001); however, increasing EBF from 1 to 5 L/min significantly negatively influences several cardiac performance 
parameters: cardiac output decreased form 2.8 ± 0.3 L/min to 1.86 ± 0.53 L/min (P < 0.001), LV end-systolic volume 
increased from 64 ± 11 mL to 83 ± 14 mL (P < 0.001), LV stroke volume decreased from 48 ± 9 mL to 40 ± 8 mL 
(P = 0.045), LV ejection fraction decreased from 43 ± 3 % to 32 ± 3 % (P < 0.001) and stroke work increased from 
2096 ± 342 mmHg mL to 3031 ± 404 mmHg mL (P < 0.001). LV end-diastolic pressure and volume were not signifi-
cantly affected.
Conclusions: The results of the present study indicate that higher levels of VA ECMO blood flow in cardiogenic shock 
may negatively affect LV function. Therefore, it appears that to mitigate negative effects on LV function, optimal VA 
ECMO blood flow should be set as low as possible to allow adequate tissue perfusion.
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Background
Extracorporeal membrane oxygenation (ECMO) in the 
venoarterial (VA) configuration is an established method 
for the treatment of severe and rapidly progressing car-
diogenic shock or refractory cardiac arrest [1–3]. In these 
critical conditions, VA ECMO may even fully substi-
tute for cardiac pumping and pulmonary gas exchange 
to maintain sufficient tissue perfusion with oxygenated 
blood. Although randomized prospective trials confirm-
ing this have yet to be performed, several retrospective 
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studies and case series demonstrating favourable out-
comes have been published [4–6].
During peripheral VA ECMO therapy, an inflow venous 
cannula is inserted into the right atrium and drains blood 
into the extracorporeal blood pump. Blood gases are then 
exchanged in the membrane oxygenator and the oxygen-
ated blood is typically returned to the descending aorta 
through a femoral arterial outflow cannula. This VA 
ECMO setting offers partial or full circulatory support; 
however, it may be associated with specific consequences 
for the failing heart. The inflow component of the VA 
ECMO circuit decreases preload and partially or com-
pletely unloads the right heart, whereas the outflow com-
ponent increases left ventricular afterload [7]. In cases of 
extremely compromised left ventricle systolic function 
combined with increased afterload and, possibly, persist-
ing (or increasing) bronchial arterial circulation or aortic 
and mitral regurgitation, the failing left ventricle becomes 
overloaded, although the right ventricle may be fully 
unloaded [7–9]. Progressive distension of the overloaded 
left ventricle with subsequent severe pulmonary edema is 
a critical condition that often requires urgent intervention 
(e.g., left ventricular assist device implantation) [3, 7–10].
Although it is clear that increasing extracorporeal 
blood flow (EBF) may increase left ventricular afterload, 
current data regarding the relationship among EBF, cen-
tral hemodynamics and left ventricular performance are 
insufficient. Several experimental and clinical studies 
have focused on the impairment of left ventricular func-
tion during ECMO in neonates with pulmonary hyper-
tension [11–16]; however, data in the literature regarding 
adult individuals with cardiogenic shock are very limited 
[17]. The objective of the present study was, therefore, to 
describe hemodynamic and left ventricular performance 
changes resulting from a gradual increase in EBF during 
VA ECMO in a porcine model of cardiogenic shock.
Methods
The present study was approved by the Charles Univer-
sity 1st Medical School Institutional Animal Care and 
Use Committee and was performed at the Animal Labo-
ratory, Department of Physiology, 1st Medical School, 
Charles University in Prague and Na Homolce Hos-
pital, Prague, Czech Republic, in accordance with Act 
No 246/1992 Coll. on the protection of animals against 
cruelty. The investigation conforms to the Guide for the 
Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication No. 85-23, 
revised 1985).
Animal model
Five female swine (Sus scrofa domestica, landrace × large 
white crossbreed), 4–5 months of age, with a mean body 
weight of 45  kg were included in the experiment. After 
a 24  h fast, general anesthesia was induced by admin-
istration of midazolam (0.3  mg/kg intramuscular) and 
ketamine hydrochloride (15–20  mg/kg intramuscular). 
Initial propofol and morphine boluses (2  mg/kg intra-
venous [18] and 0.1–0.2  mg/kg IV, respectively) were 
administered, and animals were orotracheally intubated. 
Continuous IV infusions of propofol (8–10  mg/kg/h) 
and morphine (0.1–0.2 mg/kg/h) were used to maintain 
anesthesia. The doses were adjusted according to physi-
ological parameters, photoreaction, corneal and palpe-
bral reflexes, lacrimation and spontaneous movement. 
At the conclusion of the experiment, potassium chloride 
(2 mEq/kg), in conjunction with general anesthesia, was 
used to euthanize the animals.
Bilateral femoral (arterial and venous) and jugular 
approaches were used for multiple sheath insertions 
using the standard percutaneous Seldinger technique. 
An initial rapid IV infusion of 1000 mL normal saline was 
given after anesthesia induction, followed by a continu-
ous IV drip at a rate of 100–500 mL/h to reach and main-
tain a mean right atrial pressure of 5–7 mmHg (at an EBF 
of 1 L/min). An unfractionated heparin bolus (100 U/kg 
IV) was administered after sheath placement, followed 
by a continuous IV infusion of 50 U/kg/h to maintain an 
activated clotting time of 180–250 s. Values were moni-
tored every hour using the Hemochron Junior + Micro-
coagulation System (ITC, USA).
Ventilation was provided by a Hamilton G5 ventilator 
(Hamilton Medical AG, Switzerland) set to the INTEL-
LiVENT—Adaptive Support Ventilation mode. The ven-
tilator was set to maintain an oxygen saturation (SpO2) of 
95–99 %, and an end-tidal CO2 pressure of 4.8–5.6 kPa.
ECMO
The ECMO circuit consisted of a Levitronix Centrimag 
console (Thoratec, USA), centrifugal pump, tubing set with 
HMO 70000 Adult Microporous Membrane Oxygenator 
with Softline Coating (MAQUET Cardiopulmonary AG, 
Germany) and a mechanical gas blender (Sechrist, USA). 
Biomedicus cannulae (Medtronic, USA) were introduced 
percutaneously using the standard Seldinger technique 
after repeated dilations of the femoral artery and vein. For 
the insertion of ECMO cannulas the larger diameter left or 
right femoral arteries and veins were used according to the 
preceding duplex ultrasound measurement. The venous 
inflow cannula (21 Fr) was inserted into the right atrium 
(the tip position was verified by fluoroscopy) and the 
femoral arterial outflow cannula (15 Fr) was inserted into 
the femoral artery. Blood gas parameters were monitored 
continuously in the blood leaving the oxygenator (CDI™ 
Blood Parameter Monitoring System 500, Terumo Cardio-
vascular Systems Corporation, USA). The oxygen/air flow 
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was repeatedly adjusted to maintain pO2 and pCO2 in the 
ranges of 10–15 kPa and 4.0–6.5 kPa, respectively, in blood 
leaving the oxygenator. The EBF was set to 1 L/min until 
the start of the measurements. The circuit, console func-
tion and initial settings were controlled and directed by a 
perfusionist.
Vital function and hemodynamic monitoring
Arterial pressure was measured using standard invasive 
methods with pressure transducers (Truwave, Edwards 
Lifesciences, LLC, USA) through a pigtail catheter 
inserted into the aortic arch. A Swan–Ganz catheter was 
introduced via a femoral vein to the pulmonary artery 
and pulmonary cardiac output (PCO) was measured at 
the end of each level of EBF. Electrocardiography, heart 
rate (HR), invasive blood pressures (aortic arch and 
jugular vein), pulse oximetry, capnometry and invasive 
central venous oxygen saturation were continuously 
monitored in all animals (Monitor Life Scope TR, Nihon 
Kohden, Japan; and Vigilance II, Edwards Lifesciences, 
USA). Brain oxygenation levels were measured using 
near-infrared spectroscopy (INVOS Cerebral/Somatic 
Oximeter, Somanetics, USA).
Pressure–volume analysis
A pressure–volume (PV) conductance catheter (Scisense 
7F VSL Pigtail, Transonic, USA) was introduced into the 
left ventricle from the left carotid artery through the aortic 
valve. The catheter was connected to the PV unit (Sciense 
ADV 500, Transonic, USA) and operated in admittance 
mode. Correct positioning was assessed radiographically 
by confirming optimal PV loop morphology. The volume 
was calibrated against pulmonary thermodilution (Combo 
CCO catheter, Edwards Lifesciences, USA) at baseline. The 
PV values were recorded continually during the experi-
ment, and data from five end-expiration loops at the end 
of each level of EBF were averaged and used for the analy-
sis. Collected data included end-diastolic pressure (EDP), 
end-diastolic volume (EDV), systolic blood pressure (SBP), 
end-systolic volume (ESV) and stroke work (SW) (Fig. 1).
Calculated parameters
Stroke volume (SV) was calculated as SV = EDV − ESV; 
left ventricular ejection fraction (LVEF) was calculated as 
LVEF = SV/EDV; left ventricular cardiac output (LVCO) 
was calculated as LVCO = SV × HR; recirculation minute 
volume (RecV) was calculated as RecV =  LVCO −  PCO; 
and recirculation fraction (RecF) was calculated as 
RecF = RecV/LVCO.
Cardiogenic shock induction
The most frequently used model of acute cardiogenic 
shock in large animals is coronary artery occlusion, 
ligation or embolization with subsequent myocardial 
infarction [19–21]. However, this approach is associated 
with a very high acute mortality rate [19–21]. There-
fore, we developed an alternative model of myocardial 
hypoxia. Coronary angiography was performed and, 
according to the specific coronary anatomy in each ani-
mal, the largest left main coronary artery branch (left 
anterior descending artery or left circumflex artery) was 
identified. Two coronary guide wires were then intro-
duced into the selected vessel. The first wire was used 
for the placement of a balloon catheter and the second 
for introduction of an over-the-wire export catheter 
(Medtronic, USA) with the tip distal to the end of bal-
loon. The entry of the Export catheter was connected 
to the ECMO circuit between the pump and oxygenator 
(Fig. 2). After inflation of the balloon, the coronary artery 
was perfused with venous blood at a rate of approxi-
mately 40 mL/min. Cardiogenic shock with signs of tis-
sue hypoperfusion was defined as a drop in systolic blood 
pressure to <100  mmHg and at least one of the follow-
ing criteria: increase in blood lactate to >2.0  mmol/L; 
decrease of mixed venous oxygen saturation to <50 %; or 
fall in brain tissue oxygen saturation to <50  %. In cases 
in which the above procedure was insufficient to cause 
cardiogenic shock, an additional balloon catheter was 
introduced into the periphery of the second left main 
coronary artery branch and myocardial infarction was 
induced in the respective area by inflation of the balloon.
Experimental protocol
After insertion of all catheters and establishment of 
ECMO, the animals were stabilized for 10  min. Cardio-
genic shock was then induced using the above mentioned 
procedure. If necessary, defibrillation was performed and 
Fig. 1 Parameters measured from pressure–volume loop. EDP end-
diastolic pressure, EDV end-diastolic volume, ESV end-systolic volume, 
SBP systolic blood pressure, SW stroke work
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amiodaron 150 mg was administered IV to ensure myo-
cardial electrical stabilization. After development of signs 
of tissue hypoperfusion (approximately 60–90  min) and 
an additional 10 min of stabilization, the EBF was gradu-
ally increased by 1 L/min every 5 min. Once an EBF level 
of 5  L/min was reached, it was maintained for 10  min; 
subsequently, the EBF was gradually decreased every 
5  min by 1  L/min. At an EBF level of 1  L/min, the ani-
mals were again stabilized for 10 min and a second cycle 
of stepwise EBV increase and decrease was subsequently 
performed (Fig. 2). Measurements from the end of each 
5 min interval were averaged (four data sets per animal) 
and used for further analysis.
Statistical analysis
Results are expressed as mean  ±  SEM. The differences 
among individual levels of EBF were analyzed using a 
repeated-measures one-way ANOVA with Tukey’s mul-
tiple comparison test, or using the Friedman test with 
Dunn’s multiple comparison test (for data sets without 
normal distribution); P < 0.05 was considered to be statis-
tically significant. All statistical analyses were performed 
using GraphPad Prism 5.0 software (GraphPad, USA).
Results
Myocardial hypoxia alone led to extensive myocardial 
injury sufficient to cause cardiogenic shock in four of 
five experimental animals. In one animal, an additional 
coronary artery occlusion was necessary to induce car-
diogenic shock. Two animals were defibrillated (one and 
three attempts needed, respectively) because of ventricu-
lar fibrillation. All animals survived myocardial injury 
and successfully underwent all study procedures. The 
baseline values after the development of cardiogenic 
shock were: PCO 2.81 ± 0.34 L/min; SBP 60 ± 7 mmHg; 
LVEF 43 ± 3 %; and HR 94 ± 4 beats/min.
Directly measured parameters
With increasing EBF, an increase in SBP was observed, 
from 60  ±  7  mmHg to 72  ±  7, 81  ±  6, 89  ±  7 and 
97 ± 8 mmHg, respectively (EBF 1, 2, 3, 4 and 5 L/min; 
P < 0.001) (Fig. 3a); HR decreased from 94 ± 4 beats/min 
to 89 ± 3, 84 ± 3, 80 ± 2 and 77 ± 2 beats/min, respec-
tively (EBF 1–5 L/min; P < 0.001) (Fig. 3b); PCO decreased 
from 2.81  ±  0.34  L/min to 2.49  ±  0.25, 2.21  ±  0.21, 
1.84  ±  0.31 and 1.86  ±  0.53  L/min, respectively (EBF 
1–5  L/min; P  =  0.005) (Table  1); ESV increased from 
64 ± 11 mL to 70 ± 11, 74 ± 11, 78 ± 12 and 83 ± 14 mL, 
respectively (EBF 1–5 L/min; P < 0.001) (Fig. 3c); EDV did 
not change significantly (112 ± 19, 115 ± 19, 116 ± 19, 
119 ± 19 and 123 ± 20 mL, respectively; EBF 1–5 L/min, 
P = 0.43) (Fig. 3d); and although there was only a numer-
ical increase in EDP from 17.2 ± 1.4 mmHg to 18.2 ± 0.7, 
18.6 ± 1.5, 18.9 ± 2.4 and 19.0 ± 2.9 mmHg, respectively, 
these differences were not statistically significant (EBF 
1–5  L/min; P  =  0.87) (Fig.  3e). Finally, SW increased 
from 2096 ± 342 mmHg mL to 2510 ± 335, 2752 ± 346, 
3031  ±  404 and 2884  ±  412  mmHg  mL, respectively 
(EBF 1–5 L/min; P < 0.001) (Fig. 3f ).
Calculated parameters
With increasing EBF, a decrease in SV was observed, 
from 48 ± 9 mL to 45 ± 9, 42 ± 9, 41 ± 9 and 40 ± 8 mL, 
respectively (EBF 1–5 L/min, P = 0.045) (Fig. 3g); LVEF 
decreased from 43 ± 3 % to 39 ± 2 %, 36 ± 3 %, 34 ± 3 % 
and 32 ±  3  %, respectively (EBF 1–5  L/min; P  <  0.001) 
(Fig. 3h); and LVCO decreased from 4.31 ± 0.40 L/min to 
3.90 ± 0.47, 3.49 ± 0.51, 3.21 ± 0.40 and 2.99 ± 0.38 L/
min, respectively (EBF 1–5 L/min; P  <  0.001) (Table  1). 
The RecV and RecF remained comparable across the dif-
ferent EBF levels (Table 1).
Discussion
The present study reports for the first time that in car-
diogenic shock, EBF during VA ECMO affects invasively 
measured left ventricular performance parameters in a 
flow-dependent manner.
As a result of increasing EBF in the failing heart, we 
observed an increase in SBP and decrease in HR; these 
changes tended toward the normal values. In particular, 
elevation of low SBP in cardiogenic shock, together with 
optimizing tissue perfusion parameters, are the clear-
est and most easily measurable targets for ECMO ther-
apy. However, it has been repeatedly demonstrated that 
increased SBP also leads to higher afterload, which may 
have a deleterious effect on the failing left ventricle [7]. 
Although a causal relationship between increased after-
load and depressed left ventricular function in cardio-
genic shock and VA ECMO therapy is more than likely, 
other factors (i.e., humoral factors or vegetative nervous 
Fig. 2 Induction of regional myocardial hypoxia through perfusion of 
selected coronary artery by desaturated venous blood. LAD left ante-
rior descending artery, LCx left circumflex artery, LM left main artery
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system) may also contribute to this deleterious effect. 
Nevertheless, with increasing EBF and SBP, we observed 
an increase in ESV and decrease in SV and LVEF that 
resulted in decreased cardiac output.
Although EDV and EDP values increased numerically 
with increasing EBF, these differences did not reach sta-
tistical significance. However, EDV and EDP are mark-
edly influenced not only by afterload but also by preload. 
Fig. 3 The effect of venoarterial extracorporeal membrane oxygenation blood flow on selected hemodynamic and left ventricular performance 
parameters in a porcine model of cardiogenic shock. EBF extracorporeal blood flow, EDP end-diastolic pressure, EDV end-diastolic volume, ESV 
end-systolic volume, HR heart rate, LVEF left ventricular ejection fraction, SBP systolic blood pressure, SV stroke volume, SW stroke work. *P < 0.05 
compared with value at EBF 1 L/min
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At the highest EBF level, the right ventricle is almost 
entirely unloaded and the PCO rapidly decreases, which 
most likely lowers preload on the left ventricle. On the 
other hand, the preload on the failing left ventricle dur-
ing VA ECMO may also be influenced by an increased 
fraction of bronchial circulation, and/or mitral and aortic 
regurgitation. In particular, aortic regurgitation is typi-
cally present in our experimental model due to the inser-
tion of the PV-loop catheter through the aortic valve. 
However, based on echocardiography evaluation, this 
regurgitation appears to be of little significance.
To evaluate the effect of bronchial circulation, mitral 
regurgitation and aortic regurgitation on left ventricular 
preload, we also calculated values of the parameters of 
recirculation, RecV and RecF. Interestingly, these param-
eters were not significantly influenced by EBF levels. This 
observation may also indicate that recirculation plays a 
minor role in the development of distension of the over-
loaded left ventricle, with subsequent severe pulmonary 
edema, which is frequently observed in patients with 
severely depressed left ventricular function on high-flow 
VA ECMO.
Furthermore, we also observed elevation of SW with 
increased EBF (numerically highest at an EBF level of 
4  L/min). This observation indicates that more energy 
needs to be expended by the left ventricle for each blood 
ejection at higher levels of EBF. It is unclear whether this 
increased energy demand is balanced by better coronary 
perfusion secondary to increased mean arterial pressure.
The occurrence of severe myocardial dysfunction as 
a result of VA ECMO has been acknowledged for many 
years. It has repeatedly been described in neonates 
with respiratory failure or with pulmonary hyperten-
sion [11–13], and similar findings were also observed in 
a lamb model [14]. Karr et al. [22] showed that impaired 
cardiac performance in infants is directly associated with 
ECMO therapy and that it is not a consequence of the 
primary lung disease. These studies are fully concordant 
with our results showing deterioration of left ventricular 
performance caused by VA ECMO in a flow-dependent 
manner. Shen et al. [16] have also shown that perfusion 
of coronary arteries by desaturated blood from the pul-
monary circulation may play a role in the development 
of left ventricular dysfunction during VA ECMO. This 
is a highly clinically relevant issue, with risk for not only 
myocardial but also brain hypoxia. Monitoring coronary 
blood oxygen saturation is technically difficult in clinical 
settings; however, near-infrared spectroscopy oximetry 
offers continuous noninvasive measurement of brain oxy-
gen saturation [23].
It could be argued that the myocardial left ventricular 
dysfunction that we attribute to ECMO-generated after-
load was a consequence of global myocardial hypoxia 
due to desaturated blood from the pulmonary circula-
tion. While this hypothesis cannot be fully ruled out, we 
consider it to be unlikely for several reasons: first, healthy 
animals with normal pulmonary function were used, and 
it is unlikely that severe pulmonary edema would develop 
within a few hours under our protocol; in addition, no 
signs of pulmonary edema (fluoroscopy, pulmonary 
mechanics) were observed throughout the study; second, 
we did not detect contractile dysfunction in nonaffected 
segments of the myocardium; and, finally, right ear SpO2 
was maintained within normal limits.
Numerous studies have also focused on adult patients 
with severe myocardial dysfunction undergoing VA 
ECMO, usually with emphasis on the distension of the 
overloaded left ventricle, which is frequently associated 
with severe pulmonary edema and represents a serious 
clinical issue [7–10]. We did not observe the develop-
ment of this critical condition in our study, even at the 
highest level of EBF. We also did not detect significant 
increases in EDV and EDP, although we observed numer-
ically increased values in these parameters. There are 
Table 1 The effect of venoarterial extracorporeal membrane oxygenation blood flow on selected hemodynamic param-
eters in a porcine model of cardiogenic shock
Values of all parameters, with the exception of RecF, are expressed in L/min
EBF extracorporeal blood flow; LVCO cardiac output, calculated from stroke volume (SV) and heart rate (HR) using the formula: LVCO = SV.HR; PCO cardiac output, 
measured using a pulmonary artery catheter; RecV recirculation volume, calculated using the formula: RecV = LVCO − PCO; RecF recirculation fraction, calculated using 
the formula: RecF = (RecV/LVCO) × 100
* P < 0.05 compared with value at EBF 1 L/min
EBF 1 2 3 4 5 P
LVCO 4.31 ± 0.40 3.90 ± 0.47 3.49 ± 0.51* 3.21 ± 0.40* 2.99 ± 0.38* <0.001
PCO 2.81 ± 0.34 2.49 ± 0.25 2.21 ± 0.21 1.84 ± 0.31* 1.86 ± 0.53* <0.001
RecV 1.51 ± 0.24 1.40 ± 0.41 1.28 ± 0.42 1.38 ± 0.28 1.13 ± 0.37 0.83
RecF (%) 35.0 ± 4.8 36.0 ± 7.6 36.6 ± 7.9 42.8 ± 4.9 37.9 ± 10.7 0.57
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several possible explanations for this discordance: first, 
we used an animal model of acute cardiogenic shock with 
the follow-up limited to approximately 150 min, and this 
interval may be too short for the development of left ven-
tricular distension; second, left ventricular systolic func-
tion was not sufficiently impaired in our study to develop 
left ventricular distension; and, finally, the compliance 
of otherwise healthy left ventricle with acute regional 
hypoxic/ischemic injury is too low to allow distension.
Our results are consistent with the study by Aissaoui 
et  al. [17] showing improvement in several echocardio-
graphical parameters determining left ventricular perfor-
mance in cardiogenic shock patients with decreasing VA 
ECMO flow.
The present study had several limitations. First, we 
used only five animals; however, the present research was 
a pilot study using an alternative model of cardiogenic 
shock that increases the survival rate immediately follow-
ing extensive acute myocardial injury. Second, the extent 
of myocardial injury was different due to individual coro-
nary anatomy; on the other hand, all animals fulfilled the 
defined criteria of cardiogenic shock with signs of tis-
sue hypoperfusion. Third, we used young and otherwise 
healthy animals; therefore, our experimental settings 
simulate clinical conditions in patients with cardiogenic 
shock caused by acute myocardial infarction rather than 
severe myocarditis or advanced dilated cardiomyopathy.
Conclusions
Our results demonstrate that increasing EBF in cardio-
genic shock during VA ECMO may cause impairment of 
left ventricular performance in a flow-dependent man-
ner. These data indicate that the optimal VA ECMO flow 
in cardiogenic shock should be as low as possible to allow 
adequate tissue perfusion.
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